Skip to content

Assesment of Physical Activity Level of Patients With Multiple Sclerosis: From Laboratory to Real Life

Assesment of Physical Activity Level of Patients With Multiple Sclerosis: From Laboratory to Real Life

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03928990
Acronym
ACTISEP
Enrollment
30
Registered
2019-04-26
Start date
2019-01-15
Completion date
2021-01-31
Last updated
2019-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

This study aims to assess the feasibility of a protocol determining individual moderate-to-vigorous physical activity (MVPA) thresholds, among multiple sclerosis patients, in routine medical practice.

Interventions

ActiGraph accelerometer + calibration with Cortex MetaMax3B ergospirometer

Sponsors

Centre Hospitalier Universitaire de Besancon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged 18 to 80 years old * Multiple sclerosis according to McDonald criteria ; * Expanded Disability Status Scale (EDSS) between 0 and 6.5 ; * Patient able to move with or without mechanical assistance.

Exclusion criteria

* Deterioration of neurological symptomatology within 60 day before enrollment ; * Changes brought to the multiple sclerosis treatment within 6 months before enrollment ; * Introduction of a treatment acting on spasticity or fatigue within 30 day before enrollment * Changes brought to reeducation protocol throughout the duration of the study * Patient unable to provide an effort equivalent to 3 times the resting metabolic value = 3 Metabolic Equivalent of Task (METs).

Design outcomes

Primary

MeasureTime frameDescription
Patient's feelingDay 1Patient's feeling measured at each step of the procedure, measured with Visual Analogique Scale (scored from 0 = not painful to 10 = extremely painful)

Countries

France

Contacts

Primary ContactYoshimasa Sagawa Jr., PhD
ysagawajunior@chu-besancon.fr00333 81 21 87 51

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026